Xencor, Inc. Announces Results of 2026 Annual Meeting of Stockholders and Equity Plan Amendment

On June 16, 2026, Xencor, Inc. held its 2026 Annual Meeting of Stockholders, where several key proposals were approved. Stockholders elected nine directors to serve until the 2027 Annual Meeting, including Dr. Bassil I. Dahiyat, Dr. Raymond J. Deshaies, and Dr. Ellen G. Feigal, among others. Additionally, stockholders ratified the selection of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. A significant administrative update was the approval of an amendment and restatement of the Xencor, Inc. 2023 Equity Incentive Plan, which increases the number of authorized shares available for issuance by 4,000,000 shares. Finally, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers. Approximately 86.26% of the outstanding shares were represented at the meeting. No clinical trial updates or regulatory milestones were disclosed in this filing.